Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line treatments for EGFR-driven tumors, including non-small cell lung cancer.
• Despite initial efficacy, tumor relapse remains a significant challenge, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the efficacy of hypofractionated EGFR TKI treatment (HypoTKI) compared to standard hyperfractionated EGFR TKI treatment (HyperTKI).
• To elucidate the mechanisms underlying the anti-tumor effects of HypoTKI, particularly its role in preventing tumor relapse.
• To evaluate the potential of combining HypoTKI with programmed cell death ligand-1 (PD-L1) blockade for advanced EGFR-driven tumors.

Main Methods:

• Comparison of HypoTKI and HyperTKI in preclinical models of EGFR-driven tumors.
• Analysis of immune cell infiltration and activation, focusing on T cells.
• Investigation of innate sensing pathways, including type I IFN and CXCL10 production via the Myd88 signaling pathway.
• Assessment of combination therapy with HypoTKI and PD-L1 blockade.

Main Results:

• HypoTKI demonstrated superior potency in tumor killing and relapse prevention compared to HyperTKI.
• HypoTKI enhanced innate immune sensing, leading to increased type I IFN and CXCL10 production through the Myd88 pathway.
• This enhanced immune response promoted greater tumor-specific T cell infiltration and reactivation.
• Combination therapy of HypoTKI and PD-L1 blockade effectively controlled advanced tumors and prevented relapse with manageable side effects.

Conclusions:

• Hypofractionated EGFR TKI treatment is a potent strategy for overcoming tumor relapse by leveraging T cell-mediated immunity.
• The Myd88 signaling pathway plays a crucial role in mediating the immune-enhancing effects of HypoTKI.
• Combining HypoTKI with PD-L1 blockade represents a promising first-line therapeutic approach for EGFR-driven tumors, warranting further clinical investigation.